CMS “Splits the Baby” on Aduhelm—Medicare Coverage but Only with Evidence Development for Now
Health Law Advisor
JANUARY 13, 2022
In 2021, the FDA approved the first anti-amyloid monoclonal antibody drug, Aduhelm, which is intended to trigger a response by the patient’s own immune system that destroys the accumulation of amyloid plaques. The FDA’s determination does not mandate Medicare coverage for Aduhelm. What Happens Next?
Let's personalize your content